Furthermore, it is possible to extend the FTO‐FOS‐IGF2BP1/2 axis as biomarkers to all patients with GC, regardless of their EBV infection status, and detecting the expression of this biomarker panel could predict the prognosis of GC patients. The gene discussed is FOS; the disease is gastric cancer.